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Abstract: Uterine leiomyoma is found in ~50–80% of women of a reproductive age and is the most
common reason for hysterectomy. Recently, posttranscriptional gene silencing by microRNAs (miRs)
has been reported as a mechanism for regulating gene expression stability in the pathogenesis of
uterine leiomyomas. In this study, miR microarray analysis of leiomyomas and paired myometrial
tissue revealed numerous aberrantly expressed miRs, including miR-150. In functional assays,
transfection with miR-150 mimic resulted in decreased migration and fibrosis, implying an inhibition
of leiomyoma growth. To identify the target genes of miR-150 in leiomyoma, gene set analysis
and network analysis were performed. To overcome the limitations of in silico analysis, changes
in expression levels of hallmark genes in leiomyoma after transfection with a miR-150 mimic were
also evaluated using qRT-PCR. As a result, the Akt/p27Kip1 pathway was presumed to be one of the
target pathways of miR-150. After transfecting cultured leiomyoma cells with the miR-150 mimic,
expression levels of its target gene Akt decreased, whereas those of p27Kip1 increased significantly.
Our results suggest that miR-150 affects the cell cycle regulation in uterine leiomyoma through the
Akt/p27Kip1 pathway.
Keywords: leiomyoma; microRNA 150-5p; Akt; p27Kip1
1. Introduction
Uterine leiomyoma, the most common reason for hysterectomy, is diagnosed in ~50–80% of
women of a reproductive age, resulting in high sociomedical expenses [1–4]. It is clear that ovarian
steroids are essential for the pathophysiology of leiomyoma growth, and therefore the use of drugs
targeting ovarian steroids has served as the mainstream treatment strategy [3]. However, symptomatic
uterine leiomyomas require continuous treatment until menopause, and currently available drugs are
difficult to use for long periods. Gonadotropin-releasing hormone agonists cause significant bone
loss after 6 months of therapy [5]. Ulipristal acetate, a selective progesterone receptor modulator that
has been in the spotlight for treatment of uterine leiomyoma in the past few years, has recently been
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reported to cause hepatotoxicity resulting in four cases of liver transplantation, and its safety therefore
needs to be verified [6].
For the past decade, growing evidence indicates that local expression of many autocrine/paracrine
mediators serve as key regulators of cell-cycle progression, cellular hypertrophy, extracellular
matrix accumulation, and apoptosis in the pathophysiology of uterine leiomyoma. In particular,
posttranscriptional gene silencing by microRNAs (miRs) has been reported to regulate gene expression
stability in the pathogenesis of uterine leiomyomas [7]. Previous studies have identified the expression
profile of a large number of miRs in leiomyoma and provide support for altered expression and
regulatory function of let 7, miR-21, miR-29, miR-200, and the miR-25-93-106 cluster in leiomyoma and
matched myometrium [8–12]. Correlation between miRs and leiomyoma remains poorly understood,
and identifying more links between components of the complex network in leiomyoma formation
and growth may provide information to establish future therapeutic options for the disease. A recent
study has shown that miR-122-targeted therapies have improved treatment outcomes in patients with
hepatitis C [13].
Thus, we aimed to investigate aberrantly regulated miRs in leiomyomas using microarrays and
quantitative real-time polymerase chain reaction (RT-PCR). We then identified the target genes of these
miRs and tested the effects of transfecting miR-150-5p into cultured leiomyoma cells to determine
whether it might function as a tumor suppressor in vitro.
2. Results
2.1. Clinical Characteristics and miR Profiles of Uterine Leiomyoma
Table 1 summarizes the clinical characteristics of 13 participants of this study. The median age of
the participants was 44 and the median size of the uterine leiomyoma was 7.4 cm in its largest diameter.
Table 1. Patient characteristics.
Variables N = 13
Age 44 (37–48)
Name of operation Hysterectomy
Site of leiomyoma Intramural
Size of leiomyoma 7.4 cm (3.7–12.2)
Follicular phase 10
Proliferative phase 3
Data are expressed as the median.
miR microarray analysis of leiomyomas and paired myometrial tissues revealed that numerous
miRs were aberrantly expressed in uterine leiomyoma, and the degree of abnormal miR expression
in uterine leiomyomas was evaluated using fold change (FC). With 1.5 FC as a cut-off value,
250 miRs showed aberrant expression among the 6,658 human miRs, whereas with 2.0 FC 124 miRs
showed differential expression. Finally, six miRs, three of which were upregulated (hsa-miR-483-5p,
hsa-miR-378d, and miR-196b-3p) and three of which downregulated (miR-1 50-5p, miR-139-5p, and
miR-140-3p), were found to have differential expression with a statistically significant fold change
(Table 2). After a database search and literature review, miR-150 was selected for further validation.
To confirm the miR microarray results, relative expression of miR-150 in uterine leiomyomas
and matched myometrium was validated using qRT-PCR (Figure 1), which revealed that miR-150
expression levels were reduced 0.33 times in leiomyoma compared to myometrium (p < 0.01).
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Table 2. Microarray analysis and significant fold changes of miRNAs between leiomyoma tissues and
paired myometrium.
Upregulated Downregulated
miRNA FC (SD) p Value miRNA FC (SD) p Value
hsa-miR-196b-3p 2.16 (0.39) 0.04 hsa-miR-139-5p 5.06 (2.31) 0.04
hsa-miR-483-5p 3.1 (0.63) 0.04 hsa-miR-140-3p 2.08 (0.94) 0.02
hsa-miR-378d 1.82 (0.52) 0.04 hsa-miR-150-5p 4.79 (2.29) 0.03
miRNA, microRNA; FC, fold change; SD: standard deviation.
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compared to matched myometrium (n = 13) according to qRT-PCR analysis (p < 0.01). miR-150, 
microRNA-150-5p; qRT-PCR, quantitative real-time polymerase chain reaction. (* p < 0.01). 
2.2. Effects of the miR-150 Mimic on Cell Migration and Collagen Gel Contraction 
To determine the effects of miR-150 on cell migration, cultured leiomyoma cells were transfected 
with the miR-150 mimic. Migration assays showed a significant decrease in cell number at 20 h (cell 
count: 28 vs. 20, p < 0.05, n = 4) and 24 h (cell count: 56 vs. 34. p < 0.05, n = 4) after miR-150 mimic 
transfection compared with that in miR-negative cultured leiomyoma cells, 48 h after miR-150 
transfection (Figure 2(A1,A2)). Collagen gel contractility of leiomyoma cells was evaluated using the 
collagen gel contraction assay. After 24 h of miR-150 mimic transfection, collagen gel contraction was 
significantly reduced compared with that of the control group (relative contraction gel diameter at 
24 h after transfection: 1 vs. 1.36, p < 0.05, n = 4) (Figure 2(B1,B2)). In the wound-healing assay, the 
percentage of wound closure was significantly reduced in miR-150-transfected leiomyoma cells 
(31.76 ± 0.84 vs 4.65 ± 2.36, p = 0.001, n = 4) (Figure 2(C1,C2)). 
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Figure 1. Relative expression of miR-150 was significantly decreased in uterine leiomyomas (n =
13) compared to matched myometrium (n = 13) according to qRT-PCR analysis (p < 0.01). miR-150,
microRNA-150-5p; qRT-PCR, quantitative real-time polymerase chain reaction. (* p < 0.01).
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Figure 2. Effects of miR-150 on cell migration and fibrosis of cultured leiomyoma cells. (A1,A2) miR-
150 transfection decreased the migration of cultured leiomyoma cells. Migration assays showed a 
significant decrease in cell numbers at 20 h (cell count: 28 vs. 20, p < 0.05, n = 4) and 26 h (cell count: 
56 vs. 34. p < 0.05, n = 4) after miR-150 mimic transfection compared with vehicle transfection. (B1,B2) 
miR-150 decreased fibrosis in cultured leiomyoma cells. Collagen gel contractility of leiomyoma cells 
was evaluated using the collagen gel contraction assay. After 24 h of miR-150 mimic transfection, 
collagen gel contraction was significantly less than that of the control group (relative contraction gel 
diameter at 24 h after transfection: 1 vs. 1.36, p < 0.05, n = 4). (C1,C2) Wound healing assay , the 
percentage of wound closure was significantly reduced in miR-150-transfected leiomyoma
cells (31.76 ± 0.84 vs 4.65 ± 2.36, p = 0.001, n = 4). miR-150, microRNA-150-5p. (* p < 0.05). 
2.3. Gene Set Analysis and Network Analysis of miR-150 Predicted Target Genes and Leiomyoma Related 
Genes 
To find predicted target genes of miR-150 in leiomyoma, we performed a hypergeometric test of 
378 miR-150 target genes predicted from targetscan (http://www.targetscan.org) and 109 known 
leioyoma-related genes from previously published papers [3,14–18]. As a result, a total of 7 genes-
TP53, CTNNB1, HMGA2, PIK3CB, CCND2, GSK3B, and p27Kip1 (CDKN1B), were common to both 
groups and showed a statistical significance of p-value 0.006 (Figure 3A).
Using the high confident link of STRING 10.5, the predicted target genes of miR-150 constituted 
a relatively large-scale subnetwork (Figure 3B). In gene prioritization using the STRING network, the 
target genes of miR-150 were able to predict leiomyoma genes sufficiently and showed a high AUC 
prediction power (AUC-0.7994) (Figure 3C). Among the predicted target genes, p27Kip1 (CDKN1B) 
was selected for further validation. 
B1 B2
Figure 2. Effects of miR-150 on cell migration and fibrosis of cultured leiomyoma cells. (A1,A2) miR-150
transfection decreased the migration of cultured leiomyoma cells. Migration assays showed a significant
decrease in cell numbers at 20 h (cell count: 28 vs. 20, p < 0.05, n = 4) and 26 h (cell count: 56 vs. 34.
p < 0.05, n = 4) after miR-150 mimic transfection compared with vehicle transfection. (B1,B2) miR-150
decreased fibrosis in cultured leiomyoma cells. Collagen gel contractility of leiomyoma cells was
evaluated using the collagen gel contraction assay. After 24 h of miR-150 mimic transfection, collagen
gel contraction was significantly less than that of the control group (relative contraction gel diameter
at 24 h after transfection: 1 vs. 1.36, p < 0.05, n = 4). (C1,C2) Wound healing assay, the percentage
of wound closure was significantly reduced in miR-150-transfected leiomyoma cells (31.76 ± 0.84 vs.
4.65 ± 2.36, p = 0.001, n = 4). miR-150, microRNA-150-5p. (* p < 0.05).
2.3. Gene Set Analysis and Network Analysis of miR-150 Predicted Target Genes and Leiomyoma Related Genes
To find predicted target genes of miR-150 in leiomyoma, we performed a hypergeometric test
of 378 miR-150 target genes predicted from targetscan (http://www.targetscan.org) and 109 known
leioyoma-related genes from previously published papers [3,14–18]. As a result, a total of 7 genes-TP53,
CTNNB1, HMGA2, PIK3CB, CCND2, GSK3B, and p27Kip1 (CDKN1B), were common to both groups
and showed a statistical significance of p-value 0.006 (Figure 3A).
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Figure 3. (A) Gene set analysis: predicted target genes of miR-150 contain 7 of the 109 previously 
known leiomyoma related genes. (B) In the STRING network model, the predicted target genes of 
miR-150 are forming modules of sufficient size. Akt and p27Kip1, the predicted target genes for miR-
150 in this study, was shown in yellow. (C) In gene prioritization using the STRING network, the 
target genes of miR-150 were able to predict leiomyoma genes sufficiently and showed a high AUC 
prediction power (AUC-0.7994). 
Figure 3. (A) Gene set analysis: predicted target genes of miR-150 contain 7 of the 109 previously
known leiomyoma related genes. (B) In the STRING network model, the predicted target genes of
miR-150 are forming modules of sufficient size. Akt and p27Kip1, the predicted target genes for miR-150
in this study, was shown in yellow. (C) In gene prioritization using the STRING network, the target
genes of miR-150 were able to predict leiomyoma genes sufficiently and showed a high AUC prediction
power (AUC-0.7994).
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Using the high confident link of STRING 10.5, the predicted target genes of miR-150 constituted a
relatively large-scale subnetwork (Figure 3B). In gene prioritization using the STRING network, the
target genes of miR-150 were able to predict leiomyoma genes sufficiently and showed a high AUC
prediction power (AUC-0.7994) (Figure 3C). Among the predicted target genes, p27Kip1 (CDKN1B)
was selected for further validation.
2.4. p27Kip1 mRNA Expression Levels Decrease in Leiomyoma
To confirm the network analysis results, relative expression of p27Kip1 (CDKN1B), a predicted
target gene of miR-150, in uterine leiomyomas and matched myometrium was assessed using qRT-PCR
(Figure 4). p27Kip1 mRNA expression levels decreased 0.23 times in leiomyoma tissues compared to
myometrial tissue (p < 0.01).
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disease-based database. Therefore, there may be a difference from the actual. To overcome these 
limitations, the effects of miR-150 on the expression of markers of apoptosis, invasion, fibrosis, and 
cell cycle in cultured leiomyoma cells were evaluated using qRT-PCR (Figure 5). Marker selection 
was determined by reference to review articles [14,17]. To determine transfection efficiency, miR-150 
expression was quantified 48 h after transfection of cultured leiomyoma cells with a miR-150 mimic. 
Treatment with miR-150 resulted in a 100-fold increase in miR-150 expression levels compared with 
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Figure 4. Expression of p27Kip1 mRNA was decreased 0.23 times in leiomyoma tissues (n = 7) compared
to myometrial tissue (n = 7) according to qRT-PCR analysis (p < 0.01). qRT-PCR, quantitative real-time
polymerase chain reaction. (* p < 0.01)
2.5. Effects of a miR-150 Mimic on the Expression of Markers of Cell Cycle, Invasion, Apoptosis, and Fibrosis in
Cultured Leiomyoma Cells
By in silico analysis, we identified predicted target genes of miR-150 in leiomyoma. However,
miRs act tissue specifically, wha reas STRING and Targetscan are neither tissu -based database nor
disease-based database. Therefor , there may be a diff rence from the actual. To overcome these
limit tions, the effects of miR-150 on the expression of markers of apoptosis, invasion, fibrosis, and
cell cycle in cultur d leio yoma cells were evaluated using qRT-PCR (Figure 5). Marker selection
was determined by reference to review articles [14,17]. To determine transfection efficiency, miR-150
expression was quantified 48 h after transfection of cultured l iomyom cells with a miR-150 mimic.
Treatment with miR-150 resulted in a 100-fold i crease in miR-150 expression levels compared with
that obs rved after hsa-miR-negative control treatment.
The levels of matrix metalloprot inase (MMP)-2 a d MMP9 (0.85-fold increase in MMP2, p = 0.70;
0.95-fold decrease in MMP9, p = 0.70), markers of invasion; caspase-3 (0.82-fold increase, p = 0.70), a
marker of apoptosis; and Ki67 (1.39-fold increase, p = 0.70), a marker of cell proliferation; collagen
type 1 (Col-1) (0.84-fold increase, p = 0.10), collagen type 3 alpha 1 (Col-3A1) (1.08-fold increase,
p = 1.00), connective tissue growth factor (CTGF) (1.81-fold increase, p = 0.333), fibronectin (3.52-fold
increase, p = 1.00), and transforming growth factor (TGF)-β1 (1.05-fold increase, p = 1.00), markers of
fibrosis; and p53 (0.73-fold decrease, p = 0.100) and cyclin D1 (CCND1) (1.21-fold increase, p = 0.209),
cell cycle markers were not significantly altered after miR-150 transfection. In contrast, the levels of
p27Kip1 were significantly increased after miR-150 transfection (1.29-fold increase, p = 0.026).
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150, microRNA-150-5p. (* p < 0.05). 
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Figure 5. qRT-PCR analysis of mRNA levels of markers of invasion (MMP2 and MMP9), apoptosis
(caspase 3), cell proliferation (Ki67), fibrosis (Col-1, Col3A-1, fibronectin, CTGF, and TGFβ-1), and
cell cycle (cyclin D1 and p53) 48 h after tr nsfection with the iR-150 mimic. mRNA levels of each
sample were normalized to that of GAPDH expression (n = 7). qRT-PCR, quantitative real-time
polymerase chain re ction; MMP2, matrix metalloprotei ase-2; MMP9, matrix metalloproteinase-9;
Col-1, collagen type 1; Col-3A1, collagen type 3 α1; CTGF, connective tissue growth factor; TGF-β1,
transforming growth factor β1; p27Kip1, cyclin-dependent kinase inhibitor 1B; CCND1, cyclin D1;
miR-150, microRNA-150-5p. (* p < 0.05).
Int. J. Mol. Sci. 2019, 20, 2684 8 of 18
2.6. Effects of the miR-150 Mimic on Akt and p27Kip1 Expression in Leiomyoma
The results of differential expression of hallmark genes after miR-150 mimic transfection and
in silico analysis suggested that p27Kip1 (or CDKN1B) is one of the target genes of miR-150 in
leiomyoma. However, Western blot analysis revealed increased expression of p27Kip1 after miR-150
mimic transfection (Figure 6A). Considering the posttranscriptional gene silencing effect of miRs, it
was presumed that there is a role for other genes. Additional in silico analysis suggested that Akt
(protein kinase B or PKB)–p27Kip1 pathway as a target pathway of miR-150 in uterine leiomyoma.
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Figure 6. (A,B) Western blots showing decreased Akt (p = 0.028) and pAkt (p = 0.068) and increased 
p27Kip1 protein (p = 0.043) in cultured leiomyoma cells at 48 h after miR-150 transfection. In contrast, 
PTEN expression did not change significantly (p = 0.180) after miR-150 mimic transfection (n = 6). 
Figure 6. (A,B) Western blots showing decreased Akt (p = 0.028) and pAkt (p = 0.068) and increased
p27Kip1 protein (p = 0.043) in cultured leiomyoma cells at 48 h after miR-15 transfection. In contrast,
PTEN expression did not change significantly (p = 0.180) afte iR-150 mimic transfection (n = 6).
miR-150, microRNA-150-5p; pAkt, phosphorylated Akt; PTEN, phosphatase and tensin homolog.
(* p < 0.05).
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After 48 h of treatment with the miR-150 mimic, we evaluated the expression of Akt,
phosphorylated Akt (pAkt), phosphatase and tensin homolog (PTEN), and p27Kip1 by Western
blot analysis. Decreased levels of Akt (0.670-fold decrease, p = 0.028, 60 kDa) and pAkt (0.34-fold
decrease, p = 0.068, 60 kDa) and increased levels of p27Kip1 (1.33-fold increase, p = 0.043, 27 kDa)
were observed. In contrast, the levels of PTEN, a well-known tumor suppressor that deactivates the
phosphatidylinositol 3-kinase (PI3k)-Akt pathway, did not change significantly after miR-150 mimic
transfection (0.68-fold decrease, p = 0.180, 54 kDa) (Figure 6A,B).
3. Discussion
MiRs are non-coding RNAs that regulate biological processes by pairing with the untranslated
region (UTR) of target mRNAs to repress their effective translation. MiRs play an important regulatory
role in gene expression stability. Moreover, accumulated evidence indicates the potential involvement
of genomic instability in leiomyoma formation and growth [7].
Previous studies have found that dysregulated miRs are inversely correlated with their
target genes at the protein level [19]. Patterns of inverse association of miRs with mRNA
expression in uterine leiomyomas revealed an involvement of multiple candidate pathways, including
extensive transcriptional reprogramming, cell proliferation control, decreased programmed cell death,
mitogen-activated protein kinase (MAPK), TGF-β, WNT, Janus kinase/signal transducers and activators
of transcription signaling, remodeling of cell adhesion, and cell–cell and cell–matrix interactions [19].
In a recent study, miR-29c, miR-200c, and miR-93 3 were reported to regulate cell proliferation of
leiomyoma via their effects on key cell cycle regulatory proteins including E2F transcription factor
1(E2F1), Cyclin D1 (CCND1), and CDK2 in vitro [20]. Moreover, in vivo evidence for the tumor
suppressor function of miR-29b was recently provided using a kidney capsule transplant model of
leiomyoma [21].
In this study, miR-150 was aberrantly expressed in leiomyomas. Because uterine leiomyomas are
steroid hormone–sensitive tumors, miRs associated with sex-steroid hormones in breast and prostate
cancers have also been investigated in these tumors, and Let-7, miR-21, miR-34a, miR-125b, and miR-150
were identified [14]. In particular, Let-7and miR-21 have been studied extensively. Let-7 is known
to have an antiproliferative effect on uterine leiomyomas by repressing its target gene high-mobility
group A2 (HMG A2), which is a frequently expressed protein in leiomyomas [22]. Furthermore, Let-7
may also contribute to the malignant transformation of leiomyoma. In a cohort of 35 leiomyosarcoma
patients, a significantly decreased Let-7 expression and overexpression of HMGA 2 were observed
in leiomyosarcoma tissue. In the same study, growth of leiomyosarcoma cells were repressed when
treated with a Let-7 inhibitor [23]. MiR-21 expression is also known to be dysregulated, having an
impact on cellular apoptosis and translation in leiomyoma cells [24]. In addition, a recent study
reported that miR-21 increases gene and protein expression of TGF-β3 and changes the expression of
extracellular matrix genes such as fibronectin, collagen 1A1, CTGF, Versican, and DPT in vitro [25].
Interestingly, the dysregulation of miR-21 is known to be involved not only in leiomyoma but also in
various OB/Gyn diseases such as endometrial cancer, endometriosis, preeclampsia, and fetal growth
restriction through different mechanisms [26–28].
On the other hand, how miR-150 specifically affects tumorigenesis of this disease remains unclear
even after more than a decade since the association of miR-150 with leiomyoma was reported. [29]. The
role of miR-150 is relatively well known in hematologic malignancies such as malignant lymphoma,
in which miR-150 functions as a tumor suppressor by deactivating the PI3K/Akt pathway [30]. Similarly,
our results suggest that the inhibitory function of miR-150 on leiomyomas is related to dysregulation
of the cell cycle through the Akt/p27Kip1 pathway.
The Akt pathway is tightly regulated in a normal cell and plays a central role in modulating cell
survival, proliferation, migration, differentiation, and apoptosis [31]. Peng et al. [32] reported that the
Akt pathway is activated in approximately 30% of fibroids as determined by immunohistochemistry,
and remarkably higher levels of phosphorylated (Ser473)-Akt were observed in leiomyoma tissues than
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in matched myometrial tissues using Western blot analysis. In fact, the PI3K/Akt-mTOR pathway has
been identified as one of the most upregulated signaling pathways in leiomyomas, based on evidence
from protein and transcriptional profiling of human leiomyomas, as well as in an Eker rat animal
model [33]. Moreover, the Akt inhibitor MK-2206 was found to promote caspase-independent cell
death and inhibit leiomyoma growth in a xenograft model, although its clinical use is limited owing to
the side effects [34].
Although both Akt and p27Kip1 are predicted target genes of miR-150, in silico analysis suggested
that p27Kip1 plays an important role in leiomyoma pathophysiology. However, Western blotting
demonstrated that miR-150 actually acts on Akt/p27Kip1 pathway, which shows the difference between
in silico analysis and reality. After transfection of miR-150 mimic in cultured leiomyoma cells, the
expression levels of Akt and pAkt, known to be elevated in leiomyomas, significantly decreased.
However, the expression of p27Kip1, known to be downregulated in leiomyomas, significantly
increased [31,32,34,35]. Akt can decrease p27Kip1 gene expression levels through various mechanisms,
such as targeting forkhead transcription factors, loss of PTEN function, impairing nuclear import of
p27Kip1, and phosphorylation of p27Kip1 [33,36,37].
Cell proliferation is a hallmark event in neoplasia, and a large proportion of abnormal cell
growth is cell cycle-dependent. In normal tissues, cell cycle kinase inhibitors such as p27Kip1 suppress
inappropriate responses to tumorigenic stimuli. p27Kip1 is known to block the progression of cells
from G1 to S phase, and has been demonstrated to control growth and cell cycle progression in
human uterine leiomyoma as well as in certain kinds of cancers [38,39]. In vivo, upregulation of
p27Kip1 by flavopiridol, an anticancer drug, strongly inhibits the growth of uterine leiomyoma cells
in xenografted tumors and its effects correlate with the upregulation of p27Kip1 [40]. In this study,
although miR-150 may target multiple pathways and Akt has various downstream effects, cell cycle
arrest due to overexpression of p27Kip1 is likely to contribute to decreased of migration, fibrosis, and
wound healing of cultured leiomyoma cells. Results that markers involved in extracellular matrix
proliferation have not changed after miR-150 transfection support this indirectly.
PTEN is a well-known tumor suppressor that antagonizes PI3K by converting PI(3,4,5)P3 into
PI(4,5)P2. Loss of PTEN function leads to over-activation of the PI3/Akt pathway, which is common in
cancer cells [41]. Although PTEN is not a predicted target gene of miR-150, we evaluated the expression
of PTEN in miR-150-transfected leiomyoma cells to determine whether the effects of miR-150 on
leiomyoma reflect higher levels of Akt/p27Kip1 pathway activation.
As mentioned above, not only Akt but also p27Kip1 are known miR-150 target genes. Although
miR-150 repressed Akt rather than p27Kip1 in our results, miR-150 inhibits p27Kip1 directly by binding
to the 3′ UTR of p27Kip1 mRNA in other diseases such as prostate cancer [42], which shows the
tissue-specific nature of miR expression. Moreover, miR-150 is an oncogene in several types of cancers,
including breast, gastric, and lung cancers, and upregulated miR-150 has been reported to be a poor
prognostic factor in these diseases [42–46]. However, several previous studies have reported that
miR-150 is downregulated in leiomyomas as well as in several hematologic malignancies such as
mantle cell, cutaneous T-cell, and Burkitt lymphomas [47–49]. The present study also demonstrated
that miR-150 transfection effectively reduced the migration potential of leiomyoma cells in vitro, which
suggests that miR-150 may inhibit tumor growth of cultured leiomyoma cells.
This study has several limitations. First, the results were based on an in vitro evaluation.
To elucidate the role of miR-150 in leiomyoma, in vivo studies are needed. Second, although there are
previous reports that p27Kip1 is decreased in leiomyoma compared to matched myometrium [50,51],
in order to draw a precise conclusion, reconfirming the baseline expression level of p27Kip1 in leiomyoma
using same samples which were used assessing changes of Akt and p27Kip1 after miR-150 transfection
is necessary.
In conclusion, miR-150 is aberrantly expressed in leiomyoma compared to its paired myometrium,
and miR-150 transfection decreased Akt and increased p27Kip1 expression levels. Moreover, cultured
leiomyoma cells transfected with miR-150 showed significantly decreased fibrosis and cell migration
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capacity in vitro. The present study does not address the mechanism underlying the loss of miR-150
expression in leiomyoma. As shown in Figure 3B, there are several pathways associated with miR-150 in
leiomyoma, and further study is needed regarding the role of other pathways other than the Akt/p27Kip1
pathway in the pathophysiology of leiomyoma. It is also unclear whether miR-150 reduction is the
primary cause of uterine leiomyoma or an intermediate phase of leiomyoma pathogenesis. However,
our results suggest that miR-150 affects the cell cycle regulation in uterine leiomyoma through the
Akt/p27Kip1 pathway. Although the pathogenesis of leiomyoma remains unclear, this study provides a
basis for investigating the underlying mechanisms responsible for human uterine leiomyoma.
4. Materials and Methods
4.1. Study Subjects and Tissue Specimens
Thirteen women participated in this study after providing written informed consent. Uterine
leiomyoma and adjacent myometrial (within 2 cm) tissues were collected from hysterectomy specimens
obtained from patients with symptomatic disease between June 2015 and July 2016. All tissue
samples were collected within 1 h of surgery, and tissues were stored at −80 ◦C before being used
to determine microRNA, mRNA, and protein levels by microarray, RT-PCR, and Western blotting
analyses, respectively. The tissues were rinsed in cold phosphate-buffered saline three times and then
cut into 4-mm3 pieces and placed in vials containing RNALater (Ambion, Austin, TX, USA) for nucleic
acid preservation. Tissue vials were kept at 4 ◦C for 24 h to allow penetration of RNALater. Vials were
then stored at −80 ◦C until RNA isolation. Table S1 describes where 13 samples were used in each
experiment. Study participants were not under any medication such as hormonal therapy for 3 months
prior to surgery based on the last menstrual period and endometrial histology. The study protocol was
approved by the institutional review board (3-2015-0249, approval date 26 August 2015) of Gangnam
Severance Hospital (Seoul, Korea).
4.2. Cell Culture of Leiomyoma and Myometrial Smooth Muscle Cells
Leiomyoma tissue samples obtained from women with uterine leiomyoma during hysterectomy
were cut into small pieces of approximately 2~5 mm3 in size and incubated in Dulbecco’s modified
Eagle’s medium without phenol red (Sigma–Aldrich, St Louis, MO, USA) containing collagenase type
I 2.0 mg/mL (Gibco, Waltham, MA, USA) and 1% antibiotic-antimycotic mixture containing 100 IU/mL
penicillin, 100 mg/mL streptomycin, and 10% heat-inactivated fetal bovine serum (FBS) for 45 min
at 37 ◦C in a shaker. The digested tissue was subsequently cultured using the explant method in a
humidified incubator at 37 ◦C and 5% CO2 for 2–4 h; cell passages were routinely conducted using
Versene solution-EDTA (Gibco). Of the samples obtained from 13 patients, primary single cell lines
from 9 leiomyomas were used for cell culture, because only nine leiomyoma tissue samples had a
sufficient number of cells for Western blotting and functional assays. Cultured cells from passage
numbers 2 to 4 were used in the experiments.
4.3. miR Microarray Analysis
For quality control, the RNA purity and integrity were evaluated using an ND-2000
spectrophotometer (NanoDrop, Wilmington, OH, USA) and an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). The Affymetrix Genechip miRNA 4.0 array (Affymetrix, Santa
Clara, CA, USA) was used according to the manufacturer’s instructions. RNA samples (1000 ng) were
labeled with the FlashTag Biotin RNA Labeling Kit (Genisphere, Hatfield, PA, USA). Labeled RNA
was quantified, fractionated, and hybridized to the miRNA microarray following the manufacturer’s
instructions. Labeled RNA was heated to 99 ◦C for 5 min and then to 45 ◦C for 5 min. RNA-array
hybridization was performed with agitation at 60 rotations/min for 16 h at 48 ◦C on an Affymetrix 450
Fluidics Station. Chips were washed and stained using a Genechip Fluidics Station 450 (Affymetrix).
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Next, chips were scanned using an Affymetrix GCS 3000 scanner (Affymetrix). Signal values were
computed using the Affymetrix GeneChip Command Console software.
Raw data were extracted automatically as per the Affymetrix data extraction protocol using the
Affymetrix GeneChip Command Console Software. CEL file import, miRNA level RMA + DABG,
all analysis, and result export were performed using the Affymetrix Expression Console Software.
Array data were filtered with probes annotated by species. Comparative analysis between test and
control samples was carried out using fold-change and paired T-test, in which the null hypothesis
was that no difference existed among two groups. The false discovery rate (FDR) was controlled by
adjusting the p value using the Benjamini-Hochberg algorithm. For the DEmiRNA set, hierarchical
cluster analysis was performed using complete linkage and the Euclidean distance as a measure of
similarity. Statistical tests and visualization of differentially expressed genes were conducted using the
R statistical language v. 3.1.2. software.
Intensity data file import, miRNA level robust multichip average detection above background-All
analysis, and result export were performed using the Affymetrix Expression Console Software (version
1.4.1.46). Array data were filtered using probes annotated by species. Comparative analysis between
test samples and control samples was performed using a fold-change approach. Visualization of
differentially expressed genes and statistical tests were performed using the R statistical language v.
2.15.0 software.
4.4. RNA Isolation and Quantitative Real-Time PCR
To assess miR expression levels, RNA was extracted from leiomyoma and matched myometrial
tissues using the miRVana RNA Isolation Kit (Ambion) as per the manufacturer’s instructions; 30 µL
of nuclease-free water was used to elute RNA. A Nanodrop ND-2000 spectrophotometer was used
to determine the RNA yield. A total of 10 ng of isolated RNA and the Taqman MicroRNA Reverse
Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, Baltics, Lithuania) were also used.
qRT-PCR for miRs was performed using a Taqman Universal Master Mix II, with uracil-N-glycosylase
(UNG) (Applied Biosystems), with sets for miR-150 and U6 small nuclear RNA (U6 snRNA) (Applied
Biosystems). All real-time PCR reactions were performed in triplicate using a 7300 Real Time PCR
system; 40 amplification cycles were performed. Relative expression was calculated using the
comparative threshold cycle (Ct) method, and miR levels were normalized to U6 levels [52].
To measure the mRNA levels of MMP2, MMP9, caspase-3, Ki67, Col-1, Col-3A1, CTGF, fibronectin,
TGF-β1, p53, cyclin D1, Akt, pAkt, PTEN, and p27Kip1, total RNA was isolated from cultured leiomyoma
cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA concentrations were determined
using a Nanodrop ND-2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Using
1000 ng of total RNA, cDNA was synthesized with oligo-dT (Superscript III kit, Invitrogen) in a C1000
Thermal Cycler (Bio-Rad, Hercules, California, CA, USA). The resultant cDNA mixtures were stored at
−20 ◦C. Using 2 µL of synthesized cDNA template, qRT-PCR amplification was performed using a
7300 Real Time PCR System (Applied Biosystems). The Power SYBR Green PCR master mix (Applied
Biosystems) was used for nucleic acid quantitation in RT PCR. The reaction mixture included the cDNA
template, forward and reverse primers, ribonuclease-free water, and the SYBR Green master mix at a
20-µL final reaction volume. Thermal cycling conditions were 95 ◦C for 5 min, followed by 40 cycles
of 95 ◦C for 30 s, 60 ◦C for 30 s, and 72 ◦C for 1 min, and a final extension at 72 ◦C for 5 min. The Ct
and melting curves were calculated using the 7300 software (Applied Biosystems), and each reaction
was performed in triplicate. mRNA levels for each sample was normalized to the glyceraldehyde
3-phosphate dehydrogenase (GAPDH) levels.
The primers for MMP2, MMP9, caspase-3, Ki67, Col-1, Col-3A1, CTGF, fibronectin, TGF-β1, p53,
cyclin D1, Akt, pAkt, PTEN, PI3K, p27Kip1, and GAPDH were as follows: MMP2 forward, 5′-ACC GCG
ACA AGA AGT ATG GC-3′ and reverse, 5′-CCA CTT GCG GTC ATC ATC GT-3′; MMP9 forward,
5′-CGA TGA CGA GTT GTG GTC CC-3′ and reverse, 5′-TCG TAG TTG GCC GTG GTA CT-3′; caspase
3 forward, 5′-GGA AGC GAA TCA ATG GAC TCT GG-3′ and reverse, 5′-GCA TCG ACA TCT GTA
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CCA GAC C-3′; Ki67 forward, 5′-GAA AGA GTG GCA ACC TGC CTT C-3′ and reverse, 5′-GCA
CCA AGT TTT ACT ACA TCT GCC-3′; Col-1 forward, 5′-GAG AGC ATG ACC GAT GGA TT-3′
and reverse, 5′-CCT TCT TGA GGT TGC CAG TC-3′; Col-3A1 forward, 5′- TTG TTC ATT CTT GCC
GTG TTT C -3′ and reverse, 5′-TCC TCC TAG GGC GTC CTG TT -3′; CTGF forward, 5′-CAT TAA
GAA GGG CAA AAA GTG C-3′ and reverse, 5′-CAC ACC CCA CAG AAC TTA GCC-3′; fibronectin
forward, 5′-CCA TCG CAA ACC GCT GCC AT-3′ and reverse, 5′-AAC ACT TCT CAG CTA TGG
GCT T-3′; TGF-β1 forward, 5′-TGG AAA CCC ACA ACG AAA TC-3′ and reverse, 5′-GGG TTC AGG
TAC CGC TTC TC-3′; p53 forward, 5′-GCC CAA CAA CAC CAG CTC CT-3′ and reverse, 5′-CCT
GGG CAT CCT TGA GTT CC-3′; cyclin D1 forward, 5′-TGC ATG TTC GTG GCC TCT AA-3′ and
reverse, 5′-TCG GTG TAG ATG CAC AGC TT-3′; Akt forward, 5′-TGA AAA CCT TCT GTG GGA
CC-3′ and reverse, 5′-TGG TCC TGG TTG TAG AAG GG-3′; PTEN forward, 5′-ATA CCA GGA CCA
GAG GAA ACC-3′ and reverse, 5′-TTG TCA TTA TCC GCA CGC TC-3′; p27Kip1 forward, 5′-GCA
CAC TTG TAG GAT AAG TGA AAT GG-3′ and reverse, 5′-CCT ATT CTA CCC AAC ACA GCA TTT
AC-3′; and p53 forward, 5′-GCC CAA CAA CAC CAG CTC CT-3′ and reverse, 5′-CCT GGG CAT CCT
TGA GTT CC-3′.
4.5. Target Gene Prediction for miR-150
To predict the target genes of miR-150, the effects of miR-150 on hallmark genes of the cell
cycle, invasion, apoptosis, and fibrosis were evaluated in cultured leiomyoma cells using qRT-PCR.
Next, in silico analysis was conducted. First, gene set analysis of 378 miR-150 target genes predicted
from targetscan (http://www.targetscan.org) and 109 known leioyoma-related genes from previously
published papers. Second, using the high confident link of STRING 10.5, network-based gene
prioritization was performed. Input data were as follows: [Input 1] Network: STRING 10.5 network;
[Input 2] Seed: predicted target gene list of miR-150; [Input 3] Validation Set: previously known
leiomyoma genes. In prioritizing genes, Naïve Bayes method [53] was used for network propagation.
The AUC score was used to calculate the rank of the leiomyoma-related genes.
4.6. Protein Isolation and Western Blotting Analysis
Protein extracts were prepared using RIPA lysis buffer (Thermo Fisher Scientific, Rockford,
Illinois, IL, USA) containing protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific).
Concentrations of total cell lysates were measured using a bicinchoninic acid protein assay kit (Thermo
Fisher Scientific). A total of 20 µg of total protein was mixed with 5× sample buffer and heated
at 95 ◦C for 5 min. Samples were loaded onto 10% sodium dodecyl sulfate polyacrylamide gels.
After electrophoresis, they were electrotransferred to a polyvinylidene fluoride membrane (Millipore,
Billerica, MA, USA) using a Transblot apparatus (Bio-Rad). Membranes were blocked using 5% nonfat
skim milk in Tris-buffered saline solution (10 mmol/L Tris-HCl (pH 7.4) and 0.5 mol/L NaCl) with
Tween-20 (0.1% vol/vol). Blots were probed using the following primary antibodies: anti-Akt (1:1000;
Cell Signaling Technology, Danvers, Massachusetts, MA, USA), anti-pAkt (1:1000; Cell Signaling
Technology, Danvers, MA, USA), anti-p27Kip1 (1:1000; Cell Signaling Technology, Danvers, MA,
USA), anti-PTEN (1:1000; Cell Signaling Technology, Danvers, MA, USA) and anti-GAPDH (1:2000,
Abcam, Cambridge, UK); the secondary antibody used was the horseradish peroxidase–conjugated
secondary anti-mouse or anti-rabbit antibody (1:2000; Thermo Scientific). Proteins were detected
using enhanced chemiluminescence (Santa Cruz Biotechnology, Dallas, TX, USA). Experiments were
performed in triplicate.
4.7. MiR Transfection
Cells were cultured to 70% to 80% confluence after being seeded into six-well plates and then
transfected with hsa-miR-negative as a control or with hsa-miR-150-5p (Thermo Fisher Scientific,
Waltham, MA, USA), a chemically synthesized double-stranded RNA that mimics mature endogenous
miR. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) transfection reagent was used according
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to the manufacturer’s instructions to obtain a final concentration of 50 nM. Transfected cells were
harvested 48 h after the reagent was added.
4.8. Migration Assay
Migration assays for transfected cultured cells were carried out using 8-mm pore size polycarbonate
membranes (Millipore, Billerica, MA, USA) and 24-well plates. Freshly trypsinized and washed cells
were suspended in serum-free medium, and cells (200 µL, 5 × 104 cells/well) were placed in the top
chamber of each insert; medium (600 µL) containing 10% FBS was added into the lower chambers.
After incubating for 24 h at 37 ◦C in a 5% CO2 humidified incubator, cells were fixed and stained
with crystal violet solution. Cells in the inner chamber were removed using a cotton swab, and cells
attached to the bottom side of the membrane were counted and imaged under an inverted microscope
(Olympus Corp., Shinjuku, Tokyo, Japan) at 200×magnification over 10 random fields in each well [54].
4.9. Collagen Gel Contraction Assay
A sterile solution of bovine type I collagen (Cell Biolabs, San Diego, CA, USA) was prepared
per the manufacturer’s instructions. Leiomyoma cells transfected with miR-150 were embedded
in collagen gel for three-dimensional cell culture. Briefly, leiomyoma cells were suspended in the
collagen solution (3.0 × 105 cells/mL). The collagen/cell mixture (0.5 mL/plate) was dispensed into
24-well culture plates (Corning, New York, NY, USA); the mixture was polymerized at 37 ◦C for 1 h.
Immediately after polymerization, 1 mL culture medium was added to each plate. After incubation for
72 h, the collagen gels were photographed and the gel surface area was measured [55,56].
4.10. Wound Healing Assay
Wound healing assays were performed as described previously, with minor modifications [57].
Briefly, leiomyoma cells transfected with miR-150 (5.0× 105 cells per well) were cultured in 6-well plates
until 80% confluent. The medium was replaced with serum-free medium containing the corresponding
drugs, and the medium was collected after 12 h of incubation. The confluent monolayer cells were
carefully removed using a 200 µL yellow tip and washed twice with PBS. The previous media were
added to the corresponding wells. Cells were photographed at low magnification at time intervals
of 0, 12, and 24 h. The wounded area was calculated using the following formula: (mean wounded
breadth ×mean remained breadth)/mean wounded breadth × 100 (%). Experiments were performed
independently in triplicate.
4.11. Statistical Analysis
Results are presented as mean ± standard error of the mean (SEM). The data were checked to
determine whether they met the requirements for a normal distribution using the Kolmogorov-Smirnov
test or the Shapiro-Wilk test. Continuous variables were compared using the Student t test,
Mann-Whitney U test, or Wilcoxon Signed rank test where appropriate. Fisher’s exact test was
used for gene set analysis. SPSS v.23.0 and R statistical language v.2.15.0 were used for statistical
analyses, and p < 0.05 was considered statistically significant.
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Abbreviations
FC Fold change
miR microRNA
RT-PCR Real-time polymerase chain reaction
UTR Untranslated region
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